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Background: The role of tonsillectomy in the management of adult tonsillitis remains uncertain and UK regional
variation in tonsillectomy rates persists. Patients, doctors and health policy makers wish to know the costs and
benefits of tonsillectomy against conservative management and whether therapy can be better targeted to maximise
benefits and minimise risks of surgery, hence maximising cost-effective use of resources. NATTINA incorporates
the first attempt to map current NHS referral criteria against other metrics of tonsil disease severity.
Methods/design: A UK multi-centre, randomised, controlled trial for adults with recurrent tonsillitis to compare
the clinical and cost-effectiveness of tonsillectomy versus conservative management.
An initial feasibility study comprises qualitative interviews to investigate the practicality of the protocol, including
willingness to randomise and be randomised. Approximately 20 otolaryngology staff, 10 GPs and 15 ENT patients
will be recruited over 5 months in all 9 proposed main trial participating sites.
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tonsillitis referred by a GP to secondary care. Randomisation between tonsillectomy and conservative management will
be according to a blocked allocation method in a 1:1 ratio stratified by centre and baseline disease severity.
If the pilot is successful, the main trial will recruit a further 528 patients over 18 months in all 9 participating sites. All
participants will be followed up for a total of 24 months, throughout which both primary and secondary outcome data
will be collected. The primary outcome is the number of sore throat days experienced over the 24-month follow-up. The
pilot and main trials include an embedded qualitative process evaluation.
Discussion: NATTINA is designed to evaluate the relative effectiveness and efficiency of tonsillectomy versus conservative
management in patients with recurrent sore throat who are eligible for surgery. Most adult tonsil disease and surgery has
an impact on economically active age groups, with individual and societal costs through loss of earnings and
productivity. Avoidance of unnecessary operations and prioritisation of those individuals likely to gain most from
tonsillectomy would reduce costs to the NHS and society.
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The role of tonsillectomy in the management of adult
sore throat remains uncertain, and despite demonstrable
compliance with prevailing empirical guidance [1], UK
regional variation in tonsillectomy rates persists [2]. The
2009 Cochrane review [3] identified only 1 evaluable
adult trial with just 70 participants [4] followed up for
only 90 days, and the review concluded that reasonable
levels of evidence to support clinical decisions were only
available for children. Currently there is evidence for in-
creasing numbers of admissions for severe or compli-
cated tonsillitis (e.g. peritonsillar abscess) as the number
of tonsillectomy operations has fallen over the past dec-
ade in England [5]. The management of sore throats
costs the National Health Service (NHS) over £120 mil-
lion per annum – an estimated £60 million of this for
general practitioner (GP) consultations and medical
therapy [6]. From 2011–12 in England alone, secondary
care costs included an estimated £10 million for bed
usage and around £20 million in elective adult tonsillec-
tomy [6].
The questions that patients, doctors and health policy
makers wish to answer relate to the relative costs and
benefits of tonsillectomy against conservative manage-
ment (delayed surgery) and whether there can be more
refined surgical indications to maximise such benefits,
minimise the risks and make the best use of the scarce
resources that are available.
Decision-making for tonsillitis is mostly undertaken in
primary care where there may be the greatest potential
for evolution in the patient pathway. Tonsillectomy is a
painful procedure [7], which requires an average of 14
days off work [8, 9] and has a number of less common
but intrusive complications [10] including changes in
taste and tongue sensation [11, 12]. Thus, irrespective of
its relative merits as a treatment, like all surgical inter-
vention it needs to be weighed carefully against the
alternatives.
Antibiotic overuse in unselected community populations
with viral pharyngitis is costly for health systems [13] and
efforts to try to curtail antibiotic prescription in general
practice are on-going [14]. However, different economic
considerations apply in those selected patients with more
frequent and incapacitating episodes [1]. A 3-arm compari-
son of immediate, versus no, versus delayed antibiotic pre-
scribing was examined over 15 years ago in a substantial
UK randomised controlled trial (RCT), which found the
main effect of antibiotic use was the promotion of future
medical consultations for sore throat [15]. However, the
study population in that trial included substantial numbers
of children [16], and the criteria for prescription were not
all aligned with the Centor Clinical Prediction Rule. More
importantly in the context of NATTINA, the trial related
to individual index episodes of sore throat. NATTINAconcerns the management of patients aged 16 years and
over who have had a significant disease burden for some
considerable qualifying period of time such that both they
and their referring physician feel that tonsillectomy may be
justified.
The NAtional Trial of Tonsillectomy IN Adults (NAT-
TINA) consists of a feasibility study, internal pilot and de-
finitive 9-centre randomised controlled trial with a
substantial sample size of 600 adults, with embedded quali-
tative process evaluation. The integration of qualitative re-
search within difficult-to-conduct randomised controlled
trials is recommended to improve their feasibility, design,
conduct and outcome [17]. Participants will be randomly
allocated into one of two groups – surgery or conservative
management. Our previous experience of a randomised
trial of tonsillectomy in children [18, 19], together with
other published Ear Nose and Throat (ENT) surgical trials,
highlighted the problem of retaining participants in the
non-surgical cohort, especially in a trial population, which
was reviewed only by postal survey and diary return. These
findings, along with patient and public engagement, have
influenced the trial design. The concept of deferred surgery
as the conservative management option rather than no sur-
gery is more acceptable to patients. NATTINA also keeps
the research team more closely engaged with the partici-
pants through two face-to-face clinic visits during follow-
up and, therefore, hopes to improve compliance rates and
minimise patient cross-over. The NATTINA patient in-
volvement forum also maintains patient engagement.
There has been no known previous attempt to map the
current NHS referral criteria against any other metrics of
severity. NATTINA factors-in more specific and sensitive
modelling of disease severity, which encourages patients to
apply a simple but validated estimate of sore throat severity.
Current UK surgical practice is governed by Scottish Inter-
collegiate Guideline Network (SIGN) guidance [1], which
has hitherto been audited only to measure compliance, not
validity. By carefully modelling, the costs and consequences
and setting these against surrogates of baseline severity, pa-
tients, clinicians, and health service funders will be pre-
sented with a range of options as to what should be the
preferred threshold for surgical intervention.
We hypothesise that NATTINA will demonstrate that
more severely affected individuals, who will ultimately gain
most from tonsillectomy, are more likely to be systematic-
ally and accurately characterised at an earlier stage, thus
maximising the cost-effectiveness of any surgical interven-
tion by more timely and precisely indicated intervention.
Most adult tonsil disease and surgery impacts on econom-
ically active age groups, with individual and societal costs
through loss of earnings and productivity. Patients will,
therefore, benefit from more timely and efficient manage-
ment – with less time lost from work or studies, and fewer
days’ illness. The NHS will gain through lower costs with
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through conservation of productivity in an economically ac-
tive patient population.
Methods/design
Feasibility study
Aim
The purpose of the feasibility study is to assess the practi-
cality of the proposed internal pilot and main NATTINA
trial. The feasibility study will specifically address the key
methodological issues raised via our Patient and Public In-
volvement (PPI) Group, as well as otolaryngology clinicians
and GPs consulted to date. In-depth qualitative interviews
will be used to assess the recruitment and randomisation
process, design and delivery of usual care, and the experi-
ences and acceptability of the treatments and outcome
measures.
Objectives
1) Evaluate otolaryngologists’ and recruiting specialist
nurse practitioners’ willingness to randomise and
randomly allocate patients to the treatment arms,
as well as evaluate patients’ willingness to be
randomised, taking into account the predicted
variation in severity of sore throat.
2) Define clear eligibility criteria acceptable to all
stakeholders.
3) Assess acceptability of conservative management
treatment arm for patients whose primary care
clinicians have referred them for specialist
intervention.
4) Establish primary care clinicians’ willingness to refer.
5) Investigate the feasibility and acceptability of our
proposed data collection methods and outcome
measures. Explore illness features reported to us as
of concern by our PPI Group to ensure they are
captured in trial returns: e.g. chronic sore throat,
night time sore throat and disruption of ability to
undertake not only usual activities but also leisure
pursuits. Develop participant questionnaires, weekly
sore throat and Sore Throat Alert Return (STAR)
data collection methods and storage.
6) Explore the processes of patient identification and
recruitment. Develop patient recruitment materials
including production of the standardised NATTINA
randomisation DVD.
7) Establish the NATTINA patient forum.
8) Prepare three of the nine centres to be set up to
start recruiting in week one of the internal pilot.
Study setting
Patients and staff will be recruited from nine hospitals
across England and Scotland.Target population and sample size
In-depth qualitative and cognitive interviews will be car-
ried out by a researcher on patients, ENT staff and GPs
over 5 months, or until data saturation. It is anticipated
that this will require 15 ENT patients, 20 ENT staff and
10 GP interviews, but the final number is to be deter-
mined according to qualitative research design criteria.
Patients will be adults with acute tonsillitis referred to
otolaryngology outpatient clinics for recurrent sore
throat and participating staff will be those who will be
involved in the proposed NATTINA study.
Inclusion criteria
Patients will meet the inclusion criteria for the internal
pilot and main trial (see below). ENT staff will be staff
members at participating sites who are likely to be in-
volved in the proposed NATTINA trial. GPs will be
practicing GPs.
Exclusion criteria
Patients will be excluded if they meet the exclusion cri-
teria for the internal pilot and main trial (see below).
There are no exclusion criteria for ENT staff and GPs.
Screening, recruitment and consent
Patients
ENT staff will identify patients attending referral visits
who meet the proposed NATTINA eligibility criteria
and will hand out a Participant Information Sheet (PIS)
at their clinic visit. Patients who are interested in partici-
pating in an interview, or who would like more informa-
tion, will complete an expression-of-interest form to
hand back to the research team during the clinic visit.
This form will be returned to the Newcastle Clinical Tri-
als Unit (NCTU) team who will contact the patients and
arrange an interview at a time and location convenient
for them. Written informed consent will be obtained at
the beginning of the interview. Feasibility study partici-
pants will not be asked to participate in the NATTINA
trial.
ENT staff
Multiple staff (otolaryngologists, research nurses, nurse
practitioners, clinic managers) who are likely to be in-
volved in NATTINA at each of the participating sites
will be given a PIS to read and will be invited for a face-
to-face or telephone interview. Informed consent will be
taken at the time of the interview or signed prior to
interview if via telephone.
GPs
A sample of primary care clinicians covering catchment
areas for as many participating sites as possible will be
identified by the Chief Investigator (CI), primary care
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sites. GPs will be contacted and provided with a PIS to read
before being invited to participate in a face-to-face or tele-
phone interview to explore their willingness to refer. In-
formed consent will be sought at the time of the interview
or signed prior to interview if via telephone.
Outcomes
1) Otolaryngologists’ and recruiting specialist nurse
practitioners' willingness to randomise and randomly
allocate patients to the treatment arms, as well as
their views on the eligibility criteria, patient
identification and recruitment.
2) Primary care clinicians’ willingness to refer.
3) Patients’ willingness to be randomised and their
acceptability of the conservative management
treatment arm, as well as views on the proposed
data collection methods, including weekly sore
throat alert prompts and STARs.
Success criteria
A decision-making meeting will be scheduled for the
end of the feasibility study to review the findings and to
confirm that there is sufficient support from those inter-
viewed to allow the project to continue on to the NAT-
TINA internal pilot phase.
Success criteria for the feasibility study to allow pro-
gression to the internal pilot phase will include evidence
of:
 Otolaryngology staff willing to consider participation
in the study
 Potential participants also showing willingness to
take part in the trial
 Eligibility criteria are acceptable and adequately
defined
 Treatment pathways are acceptable and adequately
defined
 Outcome measures and data collection methods are
feasible and adequately defined
 Processes of patient identification and recruitment
are feasible and adequately defined
 Patient information materials are refined
 NATTINA patient forum is established
 Three participating sites are able to start recruiting
in week one of the internal pilot
Data handling and record keeping
All interviews will be audio-recorded and transcribed
verbatim. Anonymous audio files and transcripts will be
stored electronically and kept alongside other study data.
Data will be handled, computerised and stored in ac-
cordance with the Data Protection Act 1998. Caldicottapproval will be sought during set up at each participat-
ing site to enable the collection and transfer of partici-
pant information as part of this study. All study data will
be stored for 5 years and in accordance with Good Clin-
ical Practice (GCP) and NCTU Standard Operating Pro-
cedures (SOP).Qualitative analysis (feasibility, internal pilot and main
trial)
Framework analysis will be adopted as a recommended ap-
proach for qualitative health research with objectives linked
to quantitative investigation [20]. We will use NVivo soft-
ware (http://www.qsrinternational.com) to aid indexing and
charting. The data will be repeatedly read and coded inde-
pendently by two researchers within a framework of a priori
issues and those identified by participants or emerging from
the data. Any divergence between coders will be discussed
on an on-going basis to inform the analysis and resolve di-
vergence in their interpretations of the data. Analysis will
be discussed at regular research team meetings to identify
areas for closer consideration (including negative case ana-
lysis) and to enhance credibility of the thematic framework
and interpretation [21, 22]. Qualitative work will explore
influences on both patient recruitment and on the imple-
mentation of the study interventions (e.g. the deferral of
surgery for up to 2 years). Our analysis of barriers and facil-
itators to: 1) trial participation and 2) the normalisation of
study interventions in clinical practice will be informed by
Normalization Process Theory [23]. This model considers
factors that affect implementation in four key areas; how
people make sense of a new practice (coherence); the will-
ingness of people to sign-up and commit to the new prac-
tice (cognitive participation); their ability to take on the
work required of the practice (collective action); and activity
undertaken to monitor and review the practice (reflexive
monitoring). The approach is increasingly used in studies
of the implementation of interventions in health care
(www.normalizationprocess.org). In NATTINA, we will
consider how well trial processes and interventions are in-
troduced and incorporated at each site for both patient and
professional (including both primary and secondary care)
groups.Sample size calculation
Sampling will be purposive, seeking maximum variety in
terms of location, age and sore throat severity among
male and female participants. Sample size will be deter-
mined by reaching data saturation where the research
team deem no new themes to have emerged in the 3
consecutive interviews [24]. Based on previous work by
the investigators, it is estimated that this will occur at
around 45+ participant interviews: 20 otolaryngology
staff, 15 patients and 10 GPs.
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Aim
The purpose of NATTINA is to establish the clinical and
cost-effectiveness of tonsillectomy compared with conser-
vative management for adult tonsillitis which, through ob-
servation and statistical modelling of outcomes, will
evaluate the impact of alternative sore throat patient path-
ways and develop future research. The internal pilot aims
to assess the ability to recruit to the main NATTINA trial
and ensure robust operational processes.
Internal pilot objectives
1) Ascertain if all trial processes, including patient
identification, eligibility criteria, randomisation and
data collection, work as intended and the eligibility
criteria are cohesively operational.
2) Gauge more precisely the number of potential
eligible patients identified in NATTINA screening
clinics.
3) Investigate baseline severity spectrum through
referral, recruitment and acceptability.
4) Identify barriers to patient recruitment and suggest
improvements to impact on recruitment rates.
5) Measure participant compliance with the proposed
weekly submission of number of sore throat days,
plus STARs during sore throat episodes.
6) Identify any major emerging systematic differences
between recruited participants and those who
decline to participate.
7) Collate and report reasons for participation/
ineligibility/decline.
8) Quantify missing data and measure attrition in sore
throat data.
9) Review activity against go criterion: 6 screening
clinics established, with target combined activity of
396 eligible patients screened in 6 months and target
minimum n = 72 randomised.
Main trial primary objectives
To compare the effectiveness and efficiency of tonsillec-
tomy versus conservative management for recurrent acute
tonsillitis over the 24 months following randomisation.
Main trial secondary objectives
1) Clinical effectiveness:
 To compare other metrics of sore throat severity
including responses on the Tonsillectomy
Outcome Inventory 14 (TOI 14) [25] and STARs
for any sore throat episodes experienced
 To compare Quality of Life (QOL) as measured
by the Short Form 12 Health Survey (SF-12) [26]
longitudinally during study follow-up To report the number of adverse events, visits to
the GP/walk-in clinic/Accident and Emergency
(A&E), prescriptions issued and additional
interventions required for sore throats and
related events through STAR data, and supported
by data linkage to primary care participant
records
 To adjust the estimate of effectiveness in light of
other baseline covariates including severity of
tonsillitis
 To evaluate the impact of alternative sore throat
patient pathways by observation and statistical
modelling of outcomes
 To assess to what extent trial participants are
representative of the total population of sore
throat patients referred to ENT clinics
2) Economic evaluation:
 To compare Quality-Adjusted Life Years (QALYs)
using the Area Under the Curve (AUC) method
based upon SF-6D scores derived from the SF-12
[26] responses [27] measured at baseline,
throughout the study and during any episodes of
sore throat experienced
 To compare the cost-effectiveness measured in
terms of the incremental cost per sore throat day
avoided from the perspective of the NHS and
patients over 24 months
 To compare the cost-utility based on incremental
cost per QALY gained from the perspective of the
NHS and participants over 24 months
 To compare the cost-benefits based on the
perspective of the NHS and participant’s willingness
to pay to avoid a sore throat day using the
NATTINA contingent valuation questionnaire
‘Value of Avoiding a Sore Throat Day’ administered
at baseline and information on the number of sore
throat days experienced.
3) Qualitative process evaluation: to document the
views, experiences and acceptability of patients and
clinicians regarding tonsillectomy and conservative
management, and how patient experience may shape
future research
4) Future research: to propose further research
questions based on the findings of the trial analyses
Study design and duration
This is a multi-centre, randomised, controlled surgical
trial with internal pilot and embedded qualitative
process evaluation, comparing immediate tonsillectomy
versus conservative management (delayed surgery). The
internal pilot will recruit patients over a 6-month
period and, subsequent to successful completion, the
main trial will commence and continue recruitment for
a further 18 months.
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ticipant’s 24-month follow-up visit and once all
serious adverse events (SAEs) have been followed up.
Qualitative interviews for the qualitative process
evaluation will be carried out on patients, staff and GPs
during the internal pilot and at the end of the main
trial.
Intervention
Participants randomised to the treatment arm will undergo
a tonsillectomy within 6–8 weeks of randomisation.
Control
Participants in the control arm will receive conserva-
tive management and will be asked to defer surgery
for up to 2 years. Conservative arm participants will
receive the standard non-surgical care, as normally
treated by the patients themselves or by the referring
GPs in their current practice, which typically com-
prises self-administered analgesia plus/minus ad hoc
primary care prescription of antibiotics, attendance at
walk-in centres or A&E departments for more severe
episodes. Participants will be reviewed at 12 months
post randomisation and assessed on their willingness
to remain in the delayed surgery arm.
Study setting
We will initially set up three proposed UK research sites to
start recruiting in week one of the internal pilot. This will
shortly be followed by another three pilot sites. On comple-
tion of the internal pilot, a further three research sites will
be set up for the main trial.
Target population and sample size
Participants will be adults with recurrent acute tonsillitis
who have been referred by their GP to secondary care.
A total of 72 participants at the 6 pilot sites will be re-
cruited into the 6-month internal pilot. An additional 528
participants will be recruited over a further 18 months in
all 9 participating sites. A total of 600 participants will be
recruited throughout the study. Depending on trial progres-
sion, additional sites may be set up to aid recruitment.
In-depth qualitative interviews will be carried out with 9
ENT staff, 10 GPs and 15–20 ENT patients by a researcher
as part of the qualitative process evaluation (see sample size
calculation). Patients will include those that have been re-
cruited to the NATTINA study and those who declined to
participate.
Inclusion criteria
 Age ≥ 16 years
 Recurrent sore throats that fulfil current SIGN
guidance [1] for elective tonsillectomy Subject has provided written informed consent for
participation in the study prior to any study specific
procedures
Exclusion criteria
 Under 16 years of age
 Previous tonsillectomy
 Listed directly (i.e. added to waiting list without
prior elective ENT outpatient appointment) during
emergency admission (e.g. due to peritonsillar
abscess/quinsy)
 nability to complete self-reported questionnaires and
sore throat returns
 Tonsillectomy required for other indications:
■ Primary sleep breathing disorder
■ Suspected malignancy
■ Tonsilloliths
 Equipoise influenced materially by other clinical
considerations:
■ Pregnant or breastfeeding
■ Bleeding diathesis
■ Therapeutic anticoagulation
Screening, recruitment and consent
The clinical team at the participating sites will identify
patients who have been referred for consideration of
tonsillectomy and will post a PIS along with their ap-
pointment letter. The information sheet will outline the
study and how to watch the NATTINA information
DVD on www.nattina.com. Screening will be performed
on all patients who attend an ENT referral clinic visit
with recurrent sore throat. Screening is defined as the
assessment of the NATTINA eligibility criteria at the pa-
tient’s clinic visit. Potential participants who were posted
a PIS will be shown the information DVD at their first
clinic visit (unless already viewed online) and given the
opportunity to discuss the study with the designated
member of the research team. Inclusion and exclusion
criteria will be checked and eligible patients invited to
participate in the study.
Participants will be given reasonable time (minimum
of 24 hours) to decide whether or not they would like to
participate. Those who are not given a PIS before their
clinic visit will receive a minimum of 24 hours to con-
sider, and will be invited to attend a later appointment
to consent. Eligible patients wishing to take part will be
asked to provide written informed consent by signing
and dating the Informed Consent Form (ICF), which will
be witnessed, signed and dated by a member of the re-
search team with documented, delegated responsibility
to do so. The original signed consent form will be
retained in the Investigator Site File, with a copy in the
clinical notes and a copy provided to the participant.
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cline to participate in NATTINA will be invited to pro-
vide anonymised baseline comparison data (age, gender,
an estimate of number of sore throat days over the prior
6 months and a TOI 14 questionnaire [25]). This will
allow an analysis of the comparability of the trial partici-
pants to the total pool of those referred at each of the
nine sites. Declining patients will also be informed about
the option to take part in an interview for the qualitative
process evaluation.
Randomisation
A blocked allocation method will be used to allocate
participants to the 2 intervention groups; tonsillectomy
versus conservative management, in a 1:1 ratio stratified
by centre and severity. Randomisation will be adminis-
tered centrally via NCTU using a secure web-based sys-
tem, accessed by the Principal Investigator (PI) or
delegated individual.
Primary outcome measure
The number of sore throat days as reported through
weekly ‘returns’ from the participants over a period of 24
months will be the primary outcome measure.
Secondary outcomes measures
 Responses on the TOI 14 [25] and STAR data to
measure frequency, severity, health and economic
impact of any sore throat episodes experienced
 QOL as measured by the SF-12 [26] longitudinally
during study follow-up
 The number of adverse events, visits to the GP/
walk-in clinic/A&E, prescriptions issued and
additional interventions required as collected from
GP records and other primary care linkage data
 The views and experiences of patients and clinicians
regarding tonsillectomy and conservative
management and how patient experience may shape
any future research required
Economic outcome measures
 QALYs using the AUC method based upon SF-6D
scores derived from the SF-12 [26] responses [27]
measured at baseline, throughout the study and
during any episodes of sore throat experienced
 Incremental cost per sore throat day avoided from
the perspective of the NHS and patients over 24
months to measure the cost-effectiveness
Data collection and follow-up
All participants will be followed up for 24 months from the
date of randomisation. Once consented, the participant willcomplete a baseline questionnaire booklet to be returned to
NCTU. The participating site will then randomise the par-
ticipant via the NCTU randomisation system. Participants
randomised to immediate tonsillectomy will undergo sur-
gery within 6–8 weeks of randomisation. All NATTINA
participants will be prompted weekly by their preferred
method of communication (short message service (SMS)
message, Email or Interactive Voice Response (IVR) via
telephone) to submit the number of sore throat days expe-
rienced in the previous 7 days, and requested to submit a
STAR when they experience a sore throat. Through this the
participant will provide details of the severity, use of any
over-the-counter and prescription medications, the nature
of any professional health care advice sought and the num-
ber of hours when unable to undertake usual activities
(including work/studies). An additional SF-12 [26] will also
be completed relative to the episode. The research nurse
will contact participants randomised to the surgical arm at
1 and 2 weeks after their tonsillectomy to collect data con-
cerning any adverse events. The participant will be asked to
attend 2 further clinic visits and complete follow-up ques-
tionnaire booklets at 12 and 24 months, and to complete 2
other questionnaire booklets at home at 6-month and
18-month interim points. The 12-month clinic visit will
allow participants in the conservative management group
to be assessed on their willingness to remain in the deferred
group. At their final 24-month visit these participants will
be asked whether they wish to go forward for tonsillectomy.
Adverse events and SAEs related to the study intervention
will be collected throughout the duration of the study.
Consent will be sought to access participants’ GP
health records in order to gather primary health care
usage data at the end of their 24-month follow-up. Data
collected will cover the participant’s 24-month follow-up
and 12 months prior to randomisation, and will capture
adverse events, number of contacts with primary and
secondary health care services, prescribing information
and other relevant material to support data retrieved
from STARs and post-operative research nurse tele-
phone calls (Table 1).
Qualitative process evaluation
A selection of recruited and declining patients, staff and
GPs will be invited to participate in a qualitative interview
to discuss their expectations, motivations for participation
and their views and experiences of sore throat and of the
NATTINA trial. Recruited participants who signed a con-
sent form allowing a researcher from Newcastle University
to approach them to discuss an interview will be contacted
during the internal pilot or towards the end of the main
trial and invited for an interview. Patients who decline to
participate in the main trial will be offered an expression of
interest form that they can complete and return to NCTU.
A researcher will then contact the patient and arrange an
Table 1 Data collection and time points
Measure Baseline Weekly (baseline
to 24-month FU)
Sore throat
episode
Surgery 6-month
FU
12- month
FU
18- month
FU
24- month
FU
'About You' Questionnaire X
'Value of Avoiding a Sore Throat Day'
Questionnaire
X
TOI 14 X X X X X
SF-12 X X X X X X
Health Service Utilisation
Questionnaire
X X X X X
Participant Time and Travel
Questionnaire
X
Comparison data (declining
patients)
X
Weekly alert X
Sore Throat Alert Returns (STAR) X
CRF X X X X X X
GP Linkage Data X
CRF Case Report Form, FU follow-up, SF-12 Short Form 12 Health Survey, TOI 14 Tonsillectomy Outcome Inventory 14
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ten informed consent will be obtained at the beginning of
the interview.
Data handling and record keeping
Data will be recorded by authorised staff and stored in a se-
cure web-based electronic data capture system (MACRO)
designed and maintained by NCTU hosted on secure
servers at Newcastle University. The validated database will
have restricted and limited access and data transferred from
site by remote access will be encrypted. Analysis of this data
will be undertaken by NCTU staff. Subjects will be identi-
fied by a unique study number allocated by the randomisa-
tion system, which will be used on CRFs and questionnaire
front covers. Personal details (full name, address, phone
numbers, Email address and NHS number) as well as their
preferred method of communication (SMS, Email, tele-
phone) will be collected by the research nurse once the par-
ticipant has been recruited, and the form faxed to NCTU
via SOHO 66 (secure fax to Email system) where it will be
used to send out follow-up questionnaires to participants.
Selected personal information will be inserted into a data-
base managed by an independent technology solutions
company for the sole purpose of distributing weekly sore
throat alert prompts and STARs centrally. Databases con-
taining identifiable information will be secure and password
protected.
All interviews for the qualitative process evaluation
will be audio-recorded and transcribed verbatim. Audio
files and anonymised transcripts will be securely stored
in password protected files.
Data will be handled, computerised and stored in ac-
cordance with the Data Protection Act 1998. Caldicottapproval will be sought during set-up at each participat-
ing site to enable the collection and transfer of partici-
pant information as part of this study. All study data will
be archived for 5 years and in accordance with GCP and
NCTU SOP.
Study compliance and withdrawal
Where feasible, visit windows of ±6 weeks should ensure
sufficient time is offered to facilitate scheduling appoint-
ments; non-attendance for study visits will prompt
follow-up by telephone. Participants may also be con-
tacted via telephone by the research nurse at the partici-
pating site to remind or encourage them to return
questionnaires or weekly alerts. Source data verification
will be performed by the Trial Manager at each partici-
pating site.
Participants will have the right to withdraw from the
study at any time for any reason, and without giving a
reason. The investigator will also have the right to with-
draw participants from the study intervention if he/she
judges this to be in their best interest. At the partici-
pants’ request, those in the conservative management
arm will be able to cross over into the surgical arm or
withdraw completely with no further data collected. Par-
ticipants in the tonsillectomy arm will be able to either
withdraw completely or cross over to the conservative
management arm before surgery has occurred.
Statistical analysis
The primary outcome measure of the total number of
sore throat days reported over the 24 months of follow-
up will be analysed using negative binomial regression in
order to compare any change between the NATTINA
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used – recruiting centre (as a random effect) and base-
line severity (as a fixed effect). This analysis will be
undertaken on an intention-to-treat basis; however, par-
ticipants may switch over from conservative to surgical
management. In the NATTINA design, although partici-
pants are asked to commit to ‘deferred surgery’, we an-
ticipate that a number of participants will take up the
opportunity to switch to surgery. The implication of
such cross over, which typifies surgical trials, is that the
intention-to-treat analysis will produce a very conserva-
tive estimate of the effect of tonsillectomy. We will,
therefore, undertake a planned ‘as treated’ analysis with
repeated measures corresponding to two periods of
follow-up for those participants who cross over from
medical management to tonsillectomy. The length of
these follow-up periods will act as an exposure variable
in the negative binomial regression.
QOL scores based on the SF-12 will be calculated ac-
cording to the scoring manual at baseline and 6, 12, 18
and 24 months post randomisation. The scores will be
analysed using models developed for longitudinal data.
The dependent variable will be the QOL score for an in-
dividual patient at a particular occasion. Both variation
between patients and variation between occasions nested
within patients will be modelled as random effects with
a normal distribution. Differences between groups and
changes over time will be modelled as fixed effects. The
analysis will be adjusted for the differences between
strata.
The analysis of other secondary outcomes will follow a
broadly similar strategy; repeated measures will be ana-
lysed using a random effects model with an appropriate
error structure. Should data be found to be non-
normally distributed, the use of transformations or non-
parametric approaches will be considered.
The true effect of tonsillectomy is likely to lie between
the estimate from the intention-to-treat analysis, which
is the most parsimonious account due to anticipated
cross-over into surgery, and the ‘as treated’ analysis,
which will tend to maximise the effect size of any surgi-
cal intervention. Outcome data analysis will be at the
end of the study and for Data Monitoring and Ethics
Committee (DMEC) review and will follow a full statis-
tical analysis plan developed prior to the start of any
analysis. Safety data will not be subject to statistical test-
ing. Data with missing observations due to loss to
follow-up will be examined to determine both its extent
and whether it is missing at random or is informative. If
data is missing to a sufficient extent, the use of appropri-
ate multiple imputation techniques will be considered.
In the event of incomplete follow-up on our primary
outcome for some participants we will fit an appropriate
exposure variable in the regression model.Secondary analysis will include estimation of the ef-
fects of tonsillectomy adjusted for potentially important
clinical and demographical variables.
Economic analysis
‘Within trial’ economic analyses will be carried out from
the perspective of the NHS. Costs will be based upon
the costs of the randomised interventions received and
on the use of subsequent care and services recorded on
Case Report Forms and participant-completed question-
naires. Cost falling on participants and their families will
also be recorded in a secondary analysis. Participant
costs and time away from usual activities per each type
of episode of care will be collected via questionnaire at
18 months. A micro costing exercise will be conducted
to elicit the other resources required to estimate the
costs of the surgical procedures. Other unit costs will
come from nationally available data [28] and combined
with use of service data to produce a cost for each trial
participant. Discounting will be applied to costs and out-
comes at UK recommended rates [29].
1) Cost-effectiveness analysis – based on the
incremental cost per sore throat day avoided.
2) Cost-utility analysis – based on incremental cost per
QALY gained. QALYs will be based upon responses
to the SF-12 converted into SF-6D scores using
standard algorithms. QALYs will be estimated from
the responses from the SF-6D using the AUC
method.
For both the cost-effectiveness and cost-utility
analyses the results will be presented as point
estimates of mean incremental costs and effects as
well as in stochastic analyses plots of cost and effects
and cost-effectiveness acceptability curves.
3) Cost-benefit analysis – a contingent valuation
method to allow participants to state their
preferences in monetary values [30], to avoid a sore
throat day using a participant-completed questionnaire
administered at baseline. For each randomised group
we will calculate mean willingness to pay and explore
how valuations might vary according to participant
characteristics (e.g. family income, gender, age, etc.).
The data on the willingness to pay for a sore throat day
avoided will be combined with information on number
of sore throat days experienced and on the cost per
participants. The results will be presented as point
estimates and in stochastic analysis plots of cost
and mean willingness to pay and incremental net
benefit curves.
For all economic evaluations deterministic sensitivity
analyses will be performed to explore key uncertainties.
Where appropriate these analyses will be combined with
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same ways as described above.
Sample size calculation
By recruiting 600 participants we are allowing for a total
loss to follow-up of 25 % over 24 months. Two groups
of 224 participants (providing complete data at 2 years)
gives 90 % power to detect an effect size of 0.33 (corre-
sponding mean intergroup difference of 3.6 days of sore
throat based on a pooled estimated standard deviation of
10.8 days) assuming a type 1 error rate of 2.5 %. The
sample size calculations take account of the anticipated
losses as well as predicted switch rates. We anticipate
that our loss to follow-up rate should be less than the
stated conservative estimate of 25 %, as we shall inten-
sively follow-up trial participants in both arms. Under-
lying assumptions of the sample size calculations will be
monitored by the DMEC.
Sampling for the qualitative process evaluation will be
purposive, seeking maximum variety in terms of age,
gender, phase of trial (pilot/main) and treatment arm
(including participants who cross over). Sample size will
be determined by reaching data saturation, estimated to
occur at around 15–20 ENT patient interviews, 9 ENT
staff interviews and 10 GP interviews.
Study monitoring
Trial Management Group
The trial will be managed by a Trial Management Group
(TMG) consisting of key staff members at NCTU, to-
gether with selected investigators, and will meet monthly
throughout the set-up and duration of the study.
Trial Steering Committee
A Trial Steering Committee (TSC) has been established
to provide overall supervision of the trial. The TSC con-
sists of the CI, an independent chairperson, an inde-
pendent clinician, two public members, an independent
statistician and observer members of the TMG. The
committee met prior to the start of the internal pilot
and will convene again at the end of the internal pilot,
and then annually during recruitment and for the dur-
ation of the trial.
Data Monitoring and Ethics Committee
An independent DMEC has been assembled to under-
take independent review and will monitor efficacy and
safety endpoints. The committee consists of an inde-
pendent chairperson, an independent clinician and an
independent statistician and has met for the first time to
discuss and advise on the inclusion of an interim ana-
lysis and possible adoption of a formal stopping rule for
efficacy or safety. The committee will meet at the end ofthe internal pilot and at least annually throughout the
course of the trial.
Patient and Public Involvement Group
The PPI Group will consist of several ENT patients and
will meet annually with a researcher from Newcastle
University. The group will act as a research advisory
group to discuss the design of NATTINA and any issues
that have occurred. PPI members will also be contacted
via Email for more urgent matters.
Ethical approval and confidentiality
The conduct of this study will be in accordance with the
recommendations for physicians involved in research on
human subjects adopted by the 18th World Medical
Assembly, Helsinki 1964 and later revisions. Favourable
ethical opinion from an appropriate Research Ethics Com-
mittee (REC) (North East – Tyne & Wear South) has been
obtained. NHS Research and Development (R&D) ap-
provals will be obtained at each site before recruitment
can commence. R&D approval will be obtained from the
following: The Freeman Hospital, Newcastle, Sunderland
Royal Hospital, Ninewells Hospital and Tayside Children’s
Hospital, Dundee, Glasgow Royal Infirmary, Aberdeen
Royal Infirmary, Bradford Royal Infirmary, Queen
Elizabeth Hospital, Birmingham, and Guy’s Hospital,
London before recruitment can commence. NCTU will
require a written copy of local approval documentation
before initiating each centre and accepting participants
into the study. PISs will be provided to all referred pa-
tients and written informed consent will be obtained
prior to randomisation and any study interventions.
Personal data will be regarded as strictly confidential.
To preserve anonymity, a unique participant ID will be
assigned to each participant at randomisation. Partici-
pants will be made aware via the PIS, and will give con-
sent for their contact details (name, address, phone
numbers and Email address) to be used by NCTU to
send out questionnaires, and by our commercial partner
to send out weekly alert prompts and STARs. Partici-
pants will sign a consent form giving their permission
for a researcher from Newcastle University to invite
them for an optional interview. Declining patients will
only be contacted by the researcher if an expression of
interest form has been returned. ENT staff who are in-
vited for interview will already be involved in the study
at the participating sites. GP contacts will be identified
by the CI and PI from each participating site, and invited
for interview.
Written consent will be sought from participants to
allow access to their electronic GP records for primary
health care linkage data. The participant’s NHS number,
along with their initials and date of birth, will be used to
link primary care data to the participant’s ID. No
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date of birth) will be transferred from the GP records
onto the NATTINA database.
All electronic personal information will be kept on
password protected databases with restricted access and
paper forms securely filed in a locked cabinet. Only the
clinical team at the participating sites will have access to
key data, which links study identifiers to individual data-
sets. The study will comply with the Data Protection
Act, 1998. All study records and Investigator Site Files
will be kept at site in a locked filing cabinet with re-
stricted access.
Discussion
The role of tonsillectomy for recurrent sore throat in
adults is still uncertain, and current statistics demon-
strate a decrease in the number of tonsillectomies in
recent years with an increase in the number of emergen-
cies [5, 6]. Both the NHS and primary health care ser-
vices require more evidence-based referral guidelines for
patients with recurrent acute tonsillitis. NATTINA will
estimate treatment effectiveness based on number of
sore throat episodes, sore throat severity, QOL and
number of primary/secondary health care interactions at
baseline and throughout the participant’s 24-month
follow-up. The study will also consider socio-economic
aspects and estimate the relative efficiency to the NHS
and patients. Incorporated qualitative interviews will col-
lect valuable views and experiences from patients, staff
and referring clinicians to shape guidelines and future
decision-making for tonsillitis patients. The amalgam-
ation of NATTINA outcome measures will facilitate the
modelling of future patient sore throat pathways and
provide accurate guidelines for tonsillectomy referral.
Trial status
The feasibility study has now been completed and the
first recruiting clinic for the NATTINA trial is planned
to start in April 2015.
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